ALKS.O (ALKS.O) News
Track canonical SquawkNews coverage tagged to ALKS.O, ALKS.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Alkermes rises after positive early-stage ADHD drug data
Shares of Alkermes rose 7.2% to $46.51 premarket after the company said its experimental ADHD drug, ALKS 7290, reduced symptoms in adults in an early-stage study. Patients receiving the 20 mg dose had a median 14-point r
EQUITY | Sep 21, 2026, 11:27 AM UTC
M
Alkermes reports positive Phase 1b data for ADHD drug ALKS 7290
Alkermes announced positive topline results from a Phase 1b proof-of-concept study evaluating its investigational orexin 2 receptor agonist, ALKS 7290, in adults with attention-deficit hyperactivity disorder (ADHD). The
EQUITY | Sep 21, 2026, 11:07 AM UTC